A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial

被引:11
|
作者
Kotalik, Ales [1 ]
Eaton, Anne [1 ]
Lian, Qinshu [1 ]
Serrano, Carlos [1 ]
Connett, John [1 ]
Neaton, James D. [1 ]
机构
[1] Univ Minnesota, Sch Publ Hlth, Div Biostat, 420 Delaware St SE, Minneapolis, MN 55455 USA
基金
美国国家卫生研究院;
关键词
Win ratio; composite outcomes; Multiple Risk Factor Intervention Trial; multiple endpoints; COMPOSITE END-POINTS; CLINICAL-TRIALS; RANDOMIZED-TRIALS; OUTCOMES; COMPONENTS;
D O I
10.1177/1740774519868233
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Composite outcomes, which combine multiple types of clinical events into a single outcome, are common in clinical trials. The usual analysis considers the time to first occurrence of any event in the composite. The major criticisms of such an approach are (1) this implicitly treats the outcomes as if they were of equal importance, but they often vary in terms of clinical relevance and severity, (2) study participants often experience more than one type of event, and (3) often less severe events occur before more severe ones, but the usual analysis disregards any information beyond that first event. Methods: A novel approach, referred to as the win ratio, which addresses the aforementioned criticisms of composite outcomes, is illustrated with a re-analysis of data on fatal and non-fatal cardiovascular disease time-to-event outcomes reported for the Multiple Risk Factor Intervention Trial. In this trial, 12,866 participants were randomized to a special intervention group (n = 6428) or a usual care (n = 6438) group. Non-fatal outcomes were ranked by risk of cardiovascular disease death up to 20 years after trial. In one approach, participants in the special intervention and usual care groups were first matched on coronary heart disease risk at baseline and time of enrollment. Each matched pair was categorized as a winner or loser depending on which one experienced a cardiovascular disease death first. If neither died of cardiovascular disease causes, they were evaluated on the most severe non-fatal outcome. This process continued for all the non-fatal outcomes. A second win ratio statistic, obtained from Cox partial likelihood, was also estimated. This statistic provides a valid estimate of the win ratio using multiple events if the marginal and conditional survivor functions of each outcome satisfy proportional hazards. Loss ratio statistics (inverse of win ratios) are compared to hazard ratios from the usual first event analysis. A larger 11-event composite was also considered. Results: For the 7-event cardiovascular disease composite, the previously reported first event analysis based on 581 events in the special intervention group and 652 events in the usual care group yielded a hazard ratio (95% confidence interval) of 0.89 (0.79-0.99), compared to 0.86 (0.77-0.97) and 0.91 (0.81-1.02) for the severity ranked estimates. Results for the 11-event composite also confirmed the findings of the first event analysis. Conclusion: The win ratio analysis was able to leverage information collected past the first experienced event and rank events by severity. The results were similar to and confirmed previously reported traditional first event analysis. The win ratio statistic is a useful adjunct to the traditional first event analysis for trials with composite outcomes.
引用
收藏
页码:626 / 634
页数:9
相关论文
共 48 条
  • [1] Hierarchical testing of composite endpoints: applying the win ratio to percutaneous coronary intervention versus coronary artery bypass grafting in the SYNTAX trial
    Milojevic, Milan
    Head, Stuart J.
    Andrinopoulou, Eleni-Rosalina
    Serruys, Patrick W.
    Mohr, Friedrich W.
    Tijssen, Jan G.
    Kappetein, A. Pieter
    EUROINTERVENTION, 2017, 13 (01) : 106 - 114
  • [2] The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial
    Abdalla, Safa
    Montez-Rath, Maria E.
    Parfrey, Patrick S.
    Chertow, Glenn M.
    CONTEMPORARY CLINICAL TRIALS, 2016, 48 : 119 - 124
  • [3] Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial
    Berwanger, Otavio
    Pfeffer, Marc
    Claggett, Brian
    Jering, Karola S.
    Maggioni, Aldo P.
    Steg, Philippe Gabriel
    Mehran, Roxana
    Lewis, Eldrin F.
    Zhou, Yinong
    van der Meer, Peter
    De Pasquale, Carmine
    Merkely, Bela
    Filippatos, Gerasimos
    McMurray, John J., V
    Granger, Christopher B.
    Solomon, Scott D.
    Braunwald, Eugene
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (10) : 1918 - 1927
  • [4] The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities
    Pocock, Stuart J.
    Ariti, Cono A.
    Collier, Timothy J.
    Wang, Duolao
    EUROPEAN HEART JOURNAL, 2012, 33 (02) : 176 - 182
  • [5] Mobile Health-Technology-Integrated Care for Atrial Fibrillation: A Win Ratio Analysis from the mAFA-II Randomized Clinical Trial
    Romiti, Giulio Francesco
    Guo, Yutao
    Corica, Bernadette
    Proietti, Marco
    Zhang, Hui
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2023, 123 (11) : 1042 - 1048
  • [6] The Win Ratio Approach in Bayesian Monitoring for Two-Arm Phase II Clinical Trial Designs With Multiple Time-To-Event Endpoints
    Huang, Xinran
    Wang, Jian
    Ning, Jing
    STATISTICS IN MEDICINE, 2024, 43 (30) : 5922 - 5934
  • [7] Multiple Risk Factor Intervention Trial Revisited: A New Perspective Based on Nonfatal and Fatal Composite Endpoints, Coronary and Cardiovascular, During the Trial
    Stamler, Jeremiah
    Neaton, James D.
    Cohen, Jerome D.
    Cutler, Jeffrey
    Eberly, Lynn
    Grandits, Gregory
    Kuller, Lewis H.
    Ockene, Judith
    Prineas, Ronald
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2012, 1 (05): : e003640
  • [8] Intervention costs and cost-effectiveness for a multiple-risk-factor diabetes self-management trial for Latinas: economic analysis of Viva Bien!
    Ritzwoller, Debra P.
    Sukhanova, Anna S.
    Glasgow, Russell E.
    Strycker, Lisa A.
    King, Diane K.
    Gaglio, Bridget
    Toobert, Deborah J.
    TRANSLATIONAL BEHAVIORAL MEDICINE, 2011, 1 (03) : 427 - 435
  • [9] Are vacations good for your health? The 9-year mortality experience after the multiple risk factor intervention trial
    Gump, BB
    Matthews, KA
    PSYCHOSOMATIC MEDICINE, 2000, 62 (05): : 608 - 612
  • [10] Intervention for Re-coarctation in the Single Ventricle Reconstruction Trial: Incidence, Risk and Outcomes
    Hill, Kevin D.
    Rhodes, John F.
    Aiyagari, Ranjit
    Baker, G. H.
    Bergersen, Lisa
    Chai, Paul J.
    Fleming, Gregory A.
    Fudge, J. C.
    Gillespie, Matthew J.
    Gray, Robert G.
    Hirsch, Russel
    Lee, Kyong-Jin
    Li, Jennifer S.
    Ohye, Richard G.
    Oster, Matthew E.
    Pasquali, Sara K.
    Pelech, Andrew M.
    Radtke, Wolfgang A.
    Takao, Cheryl M.
    Vincent, Julie A.
    Hornik, Christoph P.
    CIRCULATION, 2012, 126 (21)